Guggenheim Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT)
Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday morning,Benzinga reports. A number of other brokerages have also issued reports on IMVT. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Tuesday, March 4th. Jefferies Financial Group assumed coverage […]
Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday morning,Benzinga reports. A number of other brokerages have also issued reports on IMVT. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Tuesday, March 4th. Jefferies Financial Group assumed coverage […]
